DC Chemicals · Product datasheet

Vorasidenib (AG881) — Datasheet

CAT. NO. DC10439

Product page and current package options

ParameterValue
Chemical NameVorasidenib
CAS No.1644545-52-7
SynonymsVorasidenib;AG881;789Q85GA8P;6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoropropan-2-yl)-1,3,5-triazine-2,4-diamine;6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine;9UO;Vorasidenib [INN];Vorasidenib [USAN];Vorasidenib (AG881);Vorasidenib (USAN/INN);AG 881 [WHO-DD];GTPL10663;BDBM279948;NSC803600;s8611;US10028961, C
FormulaC14H13ClF6N6
M.Wt414.7366
SMILESClC1=C([H])C([H])=C([H])C(C2=NC(=NC(=N2)N([H])[C@]([H])(C([H])([H])[H])C(F)(F)F)N([H])[C@]([H])(C([H])([H])[H])C(F)(F)F)=N1
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Vorasidenib is a pan isocitrate dehydrogenase (IDH) inhibitor.

In Vitro

Vorasidenib has recently entered phase 1 clinical trials in hematologic (NCT02492737) and solid malignancies (NCT02481154) in patients with either an IDH1 or an IDH2 mutation. Preclinical studies have suggested that Vorasidenib fully penetrates the blood-brain barrier and may be a more effective option for patients with IDH1/2 mutated glioma[1].

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation